• Skip to primary navigation
  • Skip to main content
SRI InternationalSRI mobile logo

SRI International

SRI International - American Nonprofit Research Institute

  • About
    • Blog
    • Press room
  • Expertise
    • Advanced imaging systems
    • Artificial intelligence
    • Biomedical R&D services
    • Biomedical sciences
    • Computer vision
    • Cyber & formal methods
    • Education and learning
    • Innovation strategy and policy
    • National security
    • Ocean & space
    • Quantum
    • QED-C
    • Robotics, sensors & devices
    • Speech & natural language
    • Video test & measurement
  • Ventures
  • NSIC
  • Careers
  • Contact
  • 日本支社
Show Search
Hide Search
History of innovation November 16, 2021 Health, Pharmaceutical, Products, The 2000s

Cancer treatment: Pralatrexate

SRI International November 16, 2021

Cancer treatment: Pralatrexate -2009

In 2009, the U.S. FDA approved pralatrexate, a treatment for peripheral T-cell lymphoma. Research on drugs of this class began in the 1950s at SRI. A subsequent scientific collaboration among SRI, Memorial Sloan-Kettering Cancer Center, and Southern Research Institute led to clinical trials on related compounds conducted by Memorial Sloan-Kettering Cancer Center starting in the 1980s. Pralatrexate was ultimately identified as a viable clinical candidate and was licensed to Allos Therapeutics for further development in 2002.

Pralatrexate has shown enhanced efficacy with less toxicity than other therapeutic regimens. It is also being studied against other forms of cancer, including non-small-cell lung cancer.

HealthPharmaceuticalProductsThe 2000s

Share this

Facebooktwitterlinkedinmail

History of innovation Health, Pharmaceutical, Products, The 2000s

How can we help?

Once you hit send…

We’ll match your inquiry to the person who can best help you.

Expect a response within 48 hours.

Our privacy policy
Career call to action image

Make your own mark.

Search jobs
Our work

Case studies

Publications

Timeline of innovation

Areas of expertise

Blog

Institute

Leadership

Press room

Media inquiries

Compliance

Privacy policy

Careers

Job listings

Contact

SRI Ventures

Our locations

Headquarters

333 Ravenswood Ave
Menlo Park, CA 94025 USA

+1 (650) 859-2000

Subscribe to our newsletter

日本支社

SRI International

  • Privacy Policy
  • Cookies
  • DMCA
  • Copyright © 2022 SRI International